LaserBond (ASX: LBL) is a niche industrial tech company that extends the life of heavy equipment for sectors like mining and energy. It delivers strong margins and cash flow, with growth driven by acquisitions, OEM partnerships, and rising demand for refurbishment solutions. The stock trades on reasonable valuations with a dividend, offering upside if growth and momentum continue.
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
This ASX gold producer is undervalued due to limited production history, but strong early margins suggest significant profit potential and a possible near-term re-rating. It operates a low-risk open-pit mine with long reserves, resources, and added silver by-product exposure.
New Murchison Gold Limited is a small Australian gold producer operating the Crown Prince mine in Western Australia. The company recently transitioned from exploration to production and is generating strong cash flow from high-grade ore sold to Westgold Resources Limited. Exploration at nearby targets and potential underground mining could extend the project’s life and add future growth potential.
Electro Optic Systems develops remote weapon systems, counter-drone platforms and laser defence technologies for military customers. Despite strong order-book growth and rising defence demand, the company still generates operating losses and negative cash flow. Its valuation is largely based on future growth in counter-drone and directed-energy defence systems.
Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.
